Clinical Trial Update: Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a single dose of 90Y-ibritumomab tiuxetan in patients with low tumor burden, untreated or indolent non-Hodgkin lymphoma, has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN